International Conference on Drug Development

February 26-27, 2018 • Austin, TX

2018 Conference Theme:

Challenges of Public Health and Scientific Advances in the 21st Century – Leveraging Digital Technologies to Transform Drug Development and Regulatory Risk-Benefit Model(s)-Innovation in Manufacturing Technologies

The 2018 ICD2 is a Cosponsored Meeting with the FDA

The University of Texas at Austin College of Pharmacy Division of Pharmaceutics and the distinguished members of the Planning Committee welcome you to the 58th Annual International Conference on Drug Development (ICD2), February 26 & 27, 2018 at the Omni Barton Creek Resort and Conference Center in Austin, Texas, USA.

ICD2 continues its tradition of offering an informal forum for the exchange of ideas concerning the drug discovery and drug development process.

Offering the Most Informative and Up to Date Information in the Science and Regulation of Global Drug Development

ICD2 ROUND TABLE DISCUSSION: Challenges of Digital Technology and Biomedical Sciences in the 21st Century. Implementation of the 21st Century Cures Act and PDUFA VI – Leveraging Digital Technologies

Statement from FDA Commissioner Scott Gottlieb, M.D., on advancing new digital health policies to encourage innovation, bring efficiency and modernization to regulation – December 7, 2017 – Link

Opening Discussion and Q&A with:
  • Janet Woodcock, M.D., Director – Center for Drug Evaluation and Research, FDA
  • Mark McClellan, M.D., Ph.D., Director and Robert J. Margolis, MD, Professor of Business, Medicine and Policy, Duke University
Followed by a RoundTable Discussion with:
  • Ed Margerrison, Ph.D., Director. Office of Science and Engineering, FDA
  • Celia Witten, M.D., Ph.D., Deputy Director, Center for Biologics Evaluation and Research, FDA
  • Richard Moscicki, M.D., Chief Medical Officer, Executive Vice President, PhRMA
  • The Honorable James C. Greenwood, President and CEO, Biotechnology Industry Organization (BIO)

Expert Speakers

The conference brings together national and international scientists from academia, the pharmaceutical industry, the biotechnology industry and regulatory agencies for the opportunity to learn of and discuss new initiatives for finding a better way to develop new drugs as well as to improve the quality of existing drug products.


Conference Mission

To offer the most informative and up to date conference in the science and regulation of global drug development

Target Audience


This conference is intended for leaders in Academia, the Pharmaceutical and Biotechnology Industry (PhRMA, BIO, GPhA), contract research organizations, API manufacturers, and domestic and international regulatory agencies in positions to affect the science and regulation of drug discovery and development, who wish to stay abreast on the national and international initiatives affecting the development of safe and effective pharmaceutical drug products.

Why Attend ICD2?

“I do not understand why anyone who works in regulatory affairs in drug development is not at this meeting.”
Gerald J. Yakatan, Ph.D.
Founder & Chairman, IriSys, Inc.
“The tremendous strengths of the ICD2 is the fact that you have top people from the FDA, top people from industry, top people from other organizations, the legal groups, academic institutions all getting together and really trying to hash out some of the major challenges that the industry and the environment is dealing with and find ways to move forward.” 
Kenneth I. Kaitin, Ph.D.
Professor and Director • Tufts Center for the Study of Drug Development, Tufts University
“The ICD2 is an incredibly intimate setting which allows dialogue on cutting edge topics with not only senior scientists and policy makers at the FDA, but academicians and other senior scientists and executives from industry, the opportunity to exchange that dialogue and discuss those topics in not only a small, intimate conference setting, but also over three meals a day, is really a unique opportunity.  It’s not a typical conference.” 
Joanne Palmisano, M.D., FACP
Vice President, Drug Regulatory Affairs • Boehringer Ingelheim Pharmaceuticals, Inc.
“This is an unparalleled, not-to-be-missed opportunity to network with industry colleagues who are at the cutting edge of drug development and regulation, academics and legal wizards who establish and illuminate regulatory policy, and senior FDA officials. ” 
Kay Holcombe
Senior Vice President for Science Policy • Biotechnology Innovation Organization (BIO)Administration

Texas Pharmacy: The University of Texas at Austin College of Pharmacy